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The treatment of advanced and poor-risk multiple
myeloma (MM) is still a major challenge and no therapy has
proven to be curative or effective long term. Although allo-
geneic HCT has curative potential, the outcomes remain poor
due to high treatment-related mortality (TRM) after full-
intensity conditioning, high relapse rate after reduced-
intensity regimens and possibly other disease-speciﬁc issues.
Under an IRB approved protocol at the University of Michi-
gan, we enrolled 22 patients onto a phase 2 trial exploring
the feasibility and efﬁcacy of an intermediate-intensity
conditioning with ﬂudarabine and busulfan x 4 (FluBu4)
[ﬂudarabine 40mg/m2/day and busulfan 3.2mg/kg/day IV x 4
days], followed by allogeneic HCT between 2008 and 2011.
Eligible patients included those with high-risk MM, deﬁned
as unfavorable cytogenetics [t(4;14), t(14;16), t(14;20), -13,
-17p] or early relapse post autologous HCT. The median age
was 54 years (range, 45-70 years). The majority (64%) had
prior autologous HCT. The median HCT-speciﬁc comorbidity
index (HCT-CI) score was 3 (0-6), with 46% having a Karnof-
sky performance score 80%. Donor types [total (match+
mismatch)] were 12 (10+2) related and 10 (7+3) unrelated.
GVHD prophylaxis was tacrolimus / methotrexate in 20
(91%). Disease status was complete response in 3 (14%), very
good partial response in 6 (27%), partial response in 12 (54%)
and stable disease in 1 (4.5%).
All 22 patients tolerated the conditioning regimen
without early toxic deaths or graft failure. Common regimen-
related toxicities (RRT) include mucositis (19, 86%) and mild
transient liver function abnormality (13, 59%). Grade 3-4
mucositis occurred in 9 patients (41%). Cumulative incidence
of grade II-IV acute GVHD was 48% (95% conﬁdence interval
[CI]; 29-72%), grade III-IV acute GVHD was 23% (95%CI; 10-
47%) and chronic GVHD at 1 year was 55% (95%CI; 34-78%).
Cumulative incidences of relapse at 1 and 3 years were both
29% (95% CI; both 14-55%) and TRM at 100 days, 1 and 3 years
were 9% (95%CI; 2-33%), 19% (95%CI; 7-44%) and 33% (95%CI;
17-59%), respectively. Of note, TRM was due to idiopathic
pneumonia syndrome in 2 (9%) and cirrhosis in 1 (4.5%). All
had a marginal HCT-CI score of 3, 4 and 6 pre-HCT. With
a median follow-up of 9.5 months (range, 2-38 months), the
1- and 3-year overall survival was 61% (95%CI; 43-87%) and
33% (95%CI; 17-64%), and the 1- and 3-year progression free
survival was 40%(95%CI; 23-67%) and 15% (95%CI; 5-42%)
[Figure 1]. In summary, allogeneic HCT using an interme-
diate-intensity FluBu4 conditioning for high-risk MM is safe
and feasible, with similar TRM, compared with the published
reduced-intensity experience. Although disease recurrence
continues to be a major issue, this regimen is a promising
platform to combine the beneﬁt of a graft-versus-myeloma
effect with new maintenance strategies, in order tomaximize the chance of a long-term remission in poor-risk
MM patients.
Figure 1.
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Due in part to a potential graft versus myeloma effect,
allogeneic stem cell transplantation is a potentially curative
treatment modality in patients with multiple myeloma
(MM). Initial attempts have been hampered by the high
transplant-related mortality in this setting. With a reduction
of toxicity, allogeneic transplant approaches with reduced-
intensity conditioning (RIC) have been utilized, although
they are subject to continued disease progression and
relapse following transplantation. We analyze here the
experience of allografting four patients with MM in a single
institution, along a 16-years period in which a total of 152
individuals where allografted, using a reduced-intensity
conditioning regimen; three of the patients have had
previous autografts. All patients engrafted successfully and
a graft versus-myeloma effect was shown in all of them. One
patient relapsed in the face of graft versus host disease
(GVHD). Three patients have died (two as a result of GVHD)
and one is alive with a limited form of chronic GVHD. The
graft versus myeloma effect can be induced by means of
allogeneic transplantation but the morbidity and mortality
associated with the procedure leads into a relatively small
proportion of MM patients being cured.
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Relapsed or primary refractory Hodgkin's (HL) and Non
Hodgkin's lymphomas (NHL) are rescued, with the potential
of cure with autologous hematopoietic cell transplantation
(AHCT). The conditioning regimens used are considered
equal and none has demonstrated any superiority. During
the last 2 years, primarily due to Carmustine (BCNU)
unavailability, a new alternative conditioning regimen was
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(Busilvex) (3.2mg/kg/day for 3 days), Etoposide (400mg/m2/
day for 2 days) and Melphalan (140mg/m2) (BEM). We
retrospectively analysed the outcome of patients (pts) who
underwent AHCT following conditioning with the standard
BEAM and BEM regimen. The pts were stratiﬁed by age, pre-
transplantation disease phase and previous lines of treat-
ment. In total, 50 pts conditioned with BEM (group A) and 93
pts with BEAM (group B) were included. Group B pts were
selected among 184 pts who underwent AHCT with BEAM
regimen during the last decade. Stratiﬁcation by disease risk
was followed by a 1:2 selection. Fifty percent of the pts were
younger than 34 in both study groups with a range of 11-68
years old. The pts of group B were more likely to suffer from
HL (63) than NHL (30); whereas disease diagnosis for group A
was HL in 28 and NHL in 22 pts. Disease was chemoresistant
to salvage treatment in 46% of group A pts versus (vs) 23% of
group B pts. There were no other signiﬁcant differences
concerning the patients’ characteristics such as age above
median, pre-transplantation lines of treatment (1-2: 40%, 3-
4: 46%, 5: 14%), disease status (complete remission: 27%,
primary refractory: 52%, relapse: 21%), advanced stage
disease (52%). Complete remission post-AHCT was obtained
in 50% of group A and 56% of group B pts. Progression free
survival (PFS) at 2 years and overall survival (OS) were
similar among the two study group populations (66% vs 63%
and 80% vs 78% respectively). Given the fact that there were
more pts with chemoresistant disease in group A, a second
matched pair analysis was conducted upon stratiﬁcation by
disease chemosensitivity to salvage treatment instead of age
as a risk factor. Efﬁcacy was again similar for both condi-
tioning regimens. In multivariate analysis favorable factors in
terms of PFS were HL, chemosensitivity to salvage treatment
and stage <IIB whereas in terms of OS non-bulky disease,
HL and stage <IIB. Treatment related mortality (TRM) was
3.2% (3/93 pts) in group B and no TRM in group A. Detailed
toxicity associated with the two study regimens is further
analyzed. There are currently no randomized studies clari-
fying the optimal conditioning among multiple regimens in
terms of efﬁcacy and toxicity. In this study the two condi-
tioning regimens, BEAM and BEM, were found to be equiv-
alent. Additionally, the efﬁcacy of the newly designed BEM
regimen in chemoresistant and advanced stage disease is
encouraging.253
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Allogeneic stem cell transplantation (alloSCT) is a poten-
tially curative therapy for patients (pts) with Hodgkin
lymphoma (HL) relapsing after autologous SCT (autoSCT).
Myeloablative conditioning is associated with high non-
relapse mortality (NRM) in this setting and reduced-inten-
sity conditioning is often the preferred option. Historically,
we have used the combination of ﬂudarabine and intrave-
nous busulfan ormelphalan (FB/FM). Over the last 2 years we
used the combination of ﬂudarabine and treosulfan (FT).
Treosulfan is a pro-drug of a bi-functional alkylating agent
with intensive myelosuppressive as well as immunosup-
pressive properties and a relatively favorable toxicity proﬁle.It was predominantly explored in pts with myeloid malig-
nancies and there is only limited data on the expected
outcomes of this regimen in pts with lymphoidmalignancies.
We analyzed the outcomes of 27 pts with HL, given alloSCT,
after failure of a previous autoSCT. The median age was 30
years (range, 20-62), 18 male, 9 female. The donor was an
HLA matched sibling (n¼12), matched unrelated (n¼14) and
umbilical cord blood (n¼1). This was a relatively high-risk
patient groupwith 18 pts having chemo-refractory disease at
SCT and only 9 responded to the last course of therapy.
Nineteen pts were given FB/FM conditioning and the most
recent 8 pts were given FT with a total treosulfan of 30-32 g/
m2. The median follow up of surviving pts is 12 months
(range, 4-85 months). Eight pts are currently alive and
progression-free, 8 pts had NRM and 11 relapsed. All relapses
occurred within the ﬁrst year after SCT. The estimated 2-year
cumulative incidence of NRM and relapsewas 30% (95%CI 17-
53%) and 45% (95%CI 29-70%), respectively. The estimated 2-
year overall survival (OS) rate is 34% (95% CI 14-55%) and the
2-year progression-free survival (PFS) is 25% (95% CI 7-43%).
The 2-year PFS for pts with chemo-sensitive and chemo-
refractory disease was 53% (95%CI, 19-87) and 9% (95%CI, 0-
25), respectively (P ¼ .01). Pts given FB/FM conditioning had
a 2-year PFS of 16% (95%CI, 0-32) compared with pts condi-
tioned with FT who had a PFS of 63% (95%CI, 29-96, P ¼ .18).
In multivariant analysis, chemo-refractory disease was
associated with inferior PFS, HR 4.2 (1.3-13.5), P ¼ .02. There
was a trend for better PFS after FT conditioning, after
adjusting for other variables, HR 0.3 (0.1-1.2), P ¼ .08. Age,
gender and donor type were not signiﬁcant predicting
factors. In conclusion, alloSCT can salvage a subset of pts with
HL relapsing after autoSCT, but has a limited role in pts with
chemo-refractory disease at SCT. Treosulfan-based condi-
tioning is promising in this entity, andmerits further study in
larger comparative studies.254
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Multiple myeloma (MM) is an abnormal proliferation of
plasma cells in the bone marrow. High dose chemotherapy
with autologous stem cell transplantation (ASCT) is an
effective treatment for MM. Induction therapies include
immunomodulatory drugs, proteasome inhibitor, steroids
and DNA alkylating agents in single or tandem ASCT. Despite
the success of ASCT, post-ASCT progression is still a major
problem. Based on our previous work, we hypothesized that
combination of nucleoside analogs + DNA alkylators could
provide synergistic cytotoxicity and may be used as safe and
efﬁcacious conditioning therapy in an ASCT-program. We
exposed human MM cell lines to various combinations of
clofarabine (Clo) and gemcitabine (Gem) with or without
busulfan (Bu) and melphalan (Mel). At less than drug IC10
